Stanley H. Appel, MD, and Gary L. Pattee, MD, discuss RADICAVA ORS® data and their thoughts on what oral treatment means to patients.
See patient and caregiver experiences with RADICAVA®.
Learn more
ALS Expert Video Library
Learn more about RADICAVA ORS® (edaravone) and RADICAVA® (edaravone) IV for the treatment of ALS through a series of educational videos.
Hear From Your Peers
Experienced neurologists provide their insights for considering RADICAVA® treatment that has been prescribed by nearly 2000 US HCPs since August 2017.1 a (see footnote)
Providers are paid consultants.
Featured video—Nationwide Webcast Video Discussion About a Treatment in ALS
Nationwide Webcast Video Discussion About a Treatment in ALS
Considerations When Prescribing
Ghazala Hayat, MD, FAAN, explains why she recommends RADICAVA® for all of her patients who are newly diagnosed with ALS and how the inclusion criteria from the pivotal trial impacts her decision to prescribe treatment.
Considerations When Prescribing
Patient Selection for RADICAVA® (edaravone)
Melanie Taylor, MD, describes her approach to discussing treatment options for ALS, the patients she considers for RADICAVA® treatment, and the importance of patients hearing about their treatment options from a healthcare provider.
Patient Selection for RADICAVA® (edaravone)
The Efficacy of RADICAVA®
Said Beydoun, MD, FAAN, discusses clinical trial results of RADICAVA®, his use of the ALSFRS-R with his patients, and the challenges that have faced previous ALS clinical trials and how newer clinical trials are addressing them.
The Efficacy of RADICAVA®
Physician-Patient Treatment Discussions
Melanie Taylor, MD, shares her approach to treating patients with ALS, educating them on the disease state and their treatment options, including how RADICAVA® may help slow the loss of their physical function.
Physician-Patient Treatment Discussions
Incorporating RADICAVA® Into Your Treatment Considerations
Tomas Holmlund, MD, shares advice for handling in-office practicalities with RADICAVA®, including insurance and product access, and he explains why some of his patients prefer receiving treatment at an infusion center.
Incorporating RADICAVA® Into Your Treatment Considerations
Peer Perspective on Prescribing RADICAVA® (edaravone)
Melanie Taylor, MD, reviews the efficacy, safety, and data from the pivotal clinical trial of RADICAVA®, explains her experience in starting a patient on treatment and the options for treatment locations, considerations around clinical trials and prescribing RADICAVA®, and how she approaches the treatment discussion with patients.
Peer Perspective on Prescribing RADICAVA® (edaravone)
Safety and Personal Experience When Prescribing
Tomas Holmlund, MD, discusses the safety profile of RADICAVA® and how it impacts his decision to prescribe treatment.
Safety and Personal Experience When Prescribing
Add your practice to our ALS Care Locator.
Presentations
A panel of ALS experts discuss the benefits, risks, and appropriate uses of RADICAVA ORS® or RADICAVA® IV.
Providers are paid consultants.
Dr. Trevor J. Resnick
Clinical Professor, Department of Neurology
Herbert Wertheim College of Medicine
Florida International University
Miami, Florida
Dr. Caralayne Jackson
University of Texas Health Science Center
San Antonio, Texas
Dr. Jonathan Katz
California Pacific Medical Center
San Francisco, California
ALS Functional Rating Scale-Revised
Learn about the ALS Functional Rating Scale-Revised (ALSFRS-R), the measure used to evaluate the clinical efficacy of RADICAVA®.
ALS Functional Rating Scale-Revised
Pivotal Trial in ALS
Review information on the pivotal trial of RADICAVA® in ALS, including the clinical development program, key inclusion criteria, and baseline patient characteristics.
Pivotal Trial in ALS
Efficacy and Safety
Hear about primary efficacy endpoint data and safety information from the pivotal trial of RADICAVA®.
Efficacy and Safety
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of September 2022. Not independently verified. Return to content
Reference: 1. Data on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.
Explore detailed results of the pivotal trials that were discussed.
